Biodexa Pharmaceuticals Plc (BDRX)

NASDAQ: BDRX · IEX Real-Time Price · USD
0.803
-0.138 (-14.65%)
At close: Jul 19, 2024, 3:59 PM
0.810
+0.007 (0.90%)
After-hours: Jul 19, 2024, 7:57 PM EDT
-14.65%
Market Cap 189.21K
Revenue (ttm) 482,278
Net Income (ttm) -8.96M
Shares Out 236.51K
EPS (ttm) -10.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,032,518
Open 0.850
Previous Close 0.941
Day's Range 0.781 - 0.870
52-Week Range 0.670 - 9.640
Beta 1.47
Analysts Strong Buy
Price Target 8.00 (+896.64%)
Earnings Date Apr 19, 2024

About BDRX

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 21
Stock Exchange NASDAQ
Ticker Symbol BDRX
Full Company Profile

Financial Performance

In 2023, BDRX's revenue was 381,000, a decrease of -45.49% compared to the previous year's 699,000. Losses were -7.08 million, -7.54% less than in 2022.

Financial numbers in GBP Financial Statements

Analyst Forecast

According to one analyst, the rating for BDRX stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target
$8.0
(896.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 19, 2024 Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq...

1 day ago - GlobeNewsWire

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Biodexa Pharmaceuticals PLC BDRX announced progress on eRapa, its drug to treat Familial Adenomatous Polyposis (FAP), an inherited disorder characterized by cancer of the large intestine (colon) and r...

9 days ago - Benzinga

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for t...

9 days ago - Accesswire

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two Patients...

18 days ago - GlobeNewsWire

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

June 24, 2024 Biodexa Pharmaceuticals PLC Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) Overall 75% Non-progression Rate at 1...

26 days ago - GlobeNewsWire

Results of Annual General Meeting

13 June 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), an acquisition-focused clinical stage biopharmaceuti...

5 weeks ago - GlobeNewsWire

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

June 10, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Bien...

5 weeks ago - GlobeNewsWire

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

CARDIFF, UK / ACCESSWIRE / June 3, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) just announced promising phase 2 results for its newly in-licensed drug eRapa for treating familial adenomatous polyposi...

6 weeks ago - Accesswire

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking T...

2 months ago - GlobeNewsWire

Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) opened more than 100% up on Tuesday after reporting encouraging Phase 2 data for eRapa.

2 months ago - Invezz

Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting

May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyp...

2 months ago - GlobeNewsWire

Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition

Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by Biodexa,...

2 months ago - Accesswire

Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting

April 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented...

2 months ago - GlobeNewsWire

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)...

3 months ago - GlobeNewsWire

Preliminary Results for the Year Ended 31 December 2023

19 April 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals P...

3 months ago - GlobeNewsWire

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

Topline Results For Progression-Free Survival Expected In Q2 2024 CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutica...

4 months ago - Accesswire

Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone

Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin Topline data from Phase 2a program expected by year-end Safety profile established in more than 700 pa...

5 months ago - Accesswire

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival o...

5 months ago - GlobeNewsWire

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharm...

5 months ago - GlobeNewsWire

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 CARDIFF, United Kingdom, Jan. 22, 2024 (GLO...

6 months ago - GlobeNewsWire

Biodexa Appoints Ann Merchant to the Board of Directors

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (...

7 months ago - GlobeNewsWire

Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of e...

7 months ago - GlobeNewsWire

Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical comp...

7 months ago - GlobeNewsWire

Biodexa (BDRX) gained 91% in a single day: should you buy?

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is trending after favourable stock market news. The stock gained 91% in a single day and is up more than 107% in the last five days.

8 months ago - Invezz

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes

Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidon...

8 months ago - GlobeNewsWire